Resmetirom, a thyroid hormone receptor agonist, appeared to reduce
liver fat and fibrosis, as determined by biomarkers and non-invasive imaging, in
people with non-alcoholic steatohepatitis
(NASH), according
to a presentation at the 2021 International ...